| Literature DB >> 31819310 |
Tarik Catic1, Rasim Jusufovic1, Dzan Horozic2, Lana Lekic3, Vedad Tabakovic4.
Abstract
INTRODUCTION: Diabetes is the fastest growing chronic diseases worldwide and in Bosnia and Herzegovina. International standards for diabetes care have recognized the crucial role of pharmacists in diabetes management. Community pharmacists can provide services beyond medication dispensing inducing patient identification, assessment, education, referral, monitoring and behavioral counseling. Pharmacists' attitudes toward diabetes are generally positive but do not correlate with the degree of their involvement in diabetes management and frequency of providing diabetes-related services varied throughout countries. AIM: To measure pharmacists' attitude toward diabetes management and to identify pharmacy services that are currently provided to patients with diabetes.Entities:
Keywords: Community Pharmacy Services; Diabetes; Pharmacies
Mesh:
Substances:
Year: 2019 PMID: 31819310 PMCID: PMC6885234 DOI: 10.5455/medarh.2019.73.351-355
Source DB: PubMed Journal: Med Arch ISSN: 0350-199X
Descriptive characteristics of respondents . MPharm – Master of Pharmacy, MSc – Master of Sciences; PhD – Doctor of Philosophy
| N | Percentage (%) | ||
|---|---|---|---|
| Age (years) | 20-29 | 20 | 38.5% |
| 30-39 | 23 | 44.2% | |
| >=40 | 9 | 17.3% | |
| Gender | Male | 7 | 13.5% |
| Female | 45 | 86.5% | |
| Years of practice | <=5 | 29 | 55.8% |
| 6-10 | 12 | 23.1% | |
| >10 | 11 | 21.2% | |
| Pharmacy ownership | State ownership | 14 | 26.9% |
| Private ownership | 28 | 53.8% | |
| Other | 10 | 19.2% | |
| Level of education | MPharm | 49 | 94.2% |
| MPharm, Specialist | 0 | 0.0% | |
| MSc | 2 | 3.8% | |
| PhD | 1 | 1.9% | |
| Is diabetes an area that interests you? | Yes | 49 | 94.2% |
| No | 3 | 5.8% | |
| Have you ever completed special diabetes continuing education in the past? | Yes | 31 | 59.6% |
| No | 21 | 40.4% | |
Diabetes Attitude Scale-Version 3 (DAS-3) subscale scores. *IQR – Interquartile Range
| Five subsets of DAS-3 | Questions (n) | Median (IQR*) |
|---|---|---|
| Total DAS-3 | 33 | 3.7 (3.6 – 4.0) |
| Five subsets of DAS-3 | ||
| Need for special training | 5 | 4,4 (4,05-4,8) |
| Seriousness of type 2 diabetes | 7 | 3,9 (3,6-4,3) |
| Value of tight control | 7 | 3,9 (3,7-4,1) |
| Psychosocial impact of DM | 6 | 3,8 (3,4-4,1) |
| Patient autonomy | 8 | 3,4 (3,1-3,8) |
Frequency of providing diabetes related services to patients with diabetes. *IQR – Interquartile Range
| Frequency of providing this service to patients | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Never | Rarely | Often | Always | Median (IQR)* | |||||
| n | % | n | % | n | % | n | % | ||
| Services related to blood glucose monitoring | |||||||||
| Counsel on the use of a blood glucose meter, including how to obtain a blood sample | 1 | 1.9 | 6 | 11.5 | 29 | 55.8 | 16 | 30.8 | 2 (2-3) |
| Counsel on the appropriate times to check blood glucose | 0 | 0 | 9 | 17.3 | 27 | 51.9 | 16 | 30.8 | 2 (2-3) |
| Counsel on the current treatment targets for blood glucose | 0 | 0 | 12 | 23.1 | 30 | 57.7 | 10 | 19.2 | 2 (1.75-2) |
| Counsel on the interpretation of A1C results | 6 | 11.5 | 28 | 53.8 | 13 | 25 | 5 | 9.6 | 1 (1-2) |
| Provide drug therapy recommendations to the physician to help the patients goals | 18 | 34.6 | 21 | 40.4 | 12 | 23.1 | 1 | 1.9 | 1 (0-2) |
| Services related to hypoglycemia management | |||||||||
| Counsel on signs and symptoms of hypoglycemia | 3 | 5.8 | 15 | 28.8 | 27 | 51.9 | 7 | 13.5 | 2 (1-2) |
| Identify possible causes of hypoglycemia | 5 | 9.6 | 22 | 42.3 | 21 | 40.4 | 4 | 7.7 | 1 (1-2) |
| Counsel on possible treatment of hypoglycemia | 3 | 5.8 | 22 | 42.3 | 20 | 38.5 | 7 | 13.5 | 2 (1-2) |
| Services related to pharmacotherapy | |||||||||
| Prescription medications drug history | 2 | 3.8 | 7 | 13.5 | 26 | 50 | 17 | 32.7 | 2 (2-3) |
| Over-the-counter products history | 3 | 5.8 | 7 | 13.5 | 25 | 48.1 | 17 | 32.7 | 2 (2-3) |
| Nutritional supplements history | 3 | 5.8 | 6 | 11.5 | 24 | 46.2 | 19 | 36.5 | 2 (2-3) |
| Counsel on the appropriate use of syringes and needles (e.g., sharp disposal) | 7 | 13.5 | 15 | 28.8 | 17 | 32.7 | 13 | 25 | 2 (1-2.25) |
| Counsel on the appropriate storage of insulin | 5 | 9.3 | 7 | 13.5 | 13 | 25 | 27 | 51.9 | 3 (1.75-3) |
| Counsel on appropriate insulin administration (mixing insulin, injection technique, timing of injection, rotation of sites) | 5 | 9.6 | 9 | 17.3 | 15 | 28.8 | 23 | 44.2 | 2 (1-3) |
| Describe the appropriate time to administer each oral antidiabetic drug | 5 | 9.6 | 5 | 9.6 | 2 | 38.5 | 22 | 42.3 | 2 (2-3) |
| Describe potential adverse effects of each oral antidiabetic drug | 3 | 5.8 | 17 | 32.7 | 22 | 42.3 | 10 | 19.2 | 2 (2-3) |
| Services related to comorbid disease management | |||||||||
| Recommend anticoagulant therapy to the patient’s physician | 14 | 26.9 | 24 | 46.2 | 9 | 17.3 | 5 | 9.6 | 1 (0-2) |
| Provide education on the importance of controlling blood pressure in diabetes | 3 | 5.9 | 6 | 11.8 | 25 | 49 | 17 | 33.3 | 2 (2-3) |
| Provide drug therapy recommendations to the physician to help better control of blood pressure | 12 | 23.1 | 22 | 42.3 | 14 | 26.9 | 4 | 7.7 | 1 (1-2) |
| Provide education on the importance of regular screening of nephropathy (e.g., type of test) | 12 | 23.1 | 17 | 32.7 | 18 | 24.6 | 5 | 9.6 | 1 (0.75-2) |
| Provide education on the importance of regular screening for neuropathic pain | 9 | 17.3 | 17 | 32.7 | 16 | 30.8 | 7 | 13.5 | 1 (1-2) |
| Provide education on the importance of regular screening for retinopathy | 9 | 17.3 | 20 | 38.5 | 16 | 30.8 | 7 | 13.5 | 1 (1-2) |
| Counsel on prevention and therapy of diabetic foot | 5 | 9.6 | 19 | 36.5 | 18 | 34.6 | 10 | 19.2 | 2 (1-2) |
| Services related to healthy living choices | |||||||||
| Provide basic information on diet as it relates to diabetes management | 3 | 5.8 | 4 | 7.7 | 27 | 51.9 | 18 | 34.6 | 2 (2-3) |
| Provide basic information on exercise as it relates to diabetes management | 3 | 5.9 | 2 | 3.9 | 25 | 49 | 21 | 41.2 | 2 (2-3) |
Correlations between DAS-3 subscale results and all groups of diabetes services (rho values). DM - diabetes mellitus. * - Correlation is significant at the 0.05 level (2-tailed). ** Correlation is significant at the 0.01 level (2-tailed).
| Blood glucose monitoring | Hypoglycemia management | Pharmacotherapy management | Comorbid disease management | Healthy living choices | |
|---|---|---|---|---|---|
| Need for special training | 0,247 | 0,256 | 0,099 | 0,296* | 0,269 |
| Seriousness of type 2 diabetes | 0,071 | 0,254 | 0,167 | 0,290* | 0,463** |
| Value of tight control | 0,093 | 0,119 | 0,147 | -0,028 | 0,206 |
| Psychosocial impact of DM | 0,076 | 0,227 | 0,112 | -0,012 | 0,199 |
| Patient autonomy | 0,368** | 0,372** | 0,229 | 0,285* | 0,134 |